Physician profile
David Boris Cano
NPI 1437104510
$5,930.08
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $425 · 2021: $1,891 · 2022: $1,455 · 2023: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $582.39 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $489.82 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $426.85 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $398.26 | 2019-2022 | |
| Abbvie INC. | $397.19 | 2022-2023 | Durysta |
| Johnson & Johnson Surgical Vision, INC. | $364.98 | 2019-2023 | Tecnis Iol |
| Genentech USA, INC. | $343.83 | 2022-2023 | Vabysmo |
| Ocular Therapeutix, INC. | $327.74 | 2021-2023 | Dextenza |
| Horizon Therapeutics Plc | $300.52 | 2021-2022 | |
| Sight Sciences, INC. | $268.64 | 2019-2021 | |
| Dompe US, INC. | $263.79 | 2019-2022 | |
| Biotissue Holdings INC. | $263.23 | 2020-2022 | |
| Alcon Vision LLC | $229.79 | 2019-2023 | Rocklatan |
| Rayner Intraocular Lenses Limited | $213.25 | 2022-2023 | Omidria |
| Novartis Pharmaceuticals Corporation | $208.35 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $176.74 | 2019-2022 | |
| Allergan, INC. | $170.29 | 2020-2022 | |
| Dutch Ophthalmic, USA | $125.00 | 2023 | Eva, Combined Machine, Tissueblue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.24 | 2019-2021 | |
| Ivantis, INC | $99.20 | 2020 | |
| Shire North American Group INC | $64.40 | 2019 | |
| Oyster Point Pharma, INC. | $33.08 | 2022 | |
| Eyepoint US, INC. | $23.16 | 2019 | |
| Alcon Research LLC | $21.89 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Omeros Corporation | $19.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.